Abstract
Purpose
Malignant pericardial effusion is a frequent complication of advanced incurable malignancies and requires treatment. The purpose of this study was to identify prognostic factors for cytology-positive malignant pericardial effusion in patients treated by pericardial drainage.
Methods
We retrospectively analyzed a series of consecutive patients diagnosed with cytologically positive malignant pericardial effusion who were treated by pericardial drainage at the National Cancer Center Hospital, Tokyo.
Results
A total of 88 patients with pericardial effusion were treated by pericardial drainage, 60 patients were diagnosed with cytological positive malignant pericardial effusion including 32 with non-small cell lung cancer, 13 with breast cancer, 8 with gastrointestinal cancer, and 7 with miscellaneous cancers. Subxiphoid pericardiostomy was performed in 50 of the patients and percutaneous tube pericardiostomy in the other 10 patients. Malignant pericardial effusion recurred in 14 patients, and pericardial drainage was performed again in 9 of them. The median overall survival time was 6.1 months, and the 1-year survival rate was 28%. A multivariate analysis revealed the following significant negative prognostic factors: performance status, development of malignant pericardial effusion during chemotherapy, mediastinal lymph node enlargement, and cytologic type. (P = 0.03, 0.02, 0.01, 0.001, respectively).
Conclusion
Patients with poor prognostic factors may be better to consider as indication of palliative therapy, even if oncologic emergency had been resolved rapidly by drainage.
Similar content being viewed by others
References
Theologides A. Neoplastic cardiac tamponade. Semin Oncol 1978;5:181–2
Thurber D, Edwards J, Anchor R. Secondary tumors of the pericardium. Circulation 1962;26:228–41
Abraham KP, Reddy V, Gattuso P. Neoplasms metastatic to the hearts: review of 3314 consecutive autopsies. Am J Cardiovasc Pahtol 1990;3:195–8
Wilkes JD, Fidias P, Vaickus L, Prez RP. Malignancy-related pericardial effusion. 127 cases from the Rosewell Park Cancer Institute. Cancer 1995;76:1377–87
Savage DD, et al. Prevalence and correlates of posterior extra echocardiographic spaces in a free-living population based sample. Am J Cardiol 1998;51:1207–12
Shepherd FA, et al. Medical management of malignant pericardial effusion by tetracycline sclerosis. Am J Cardiol 1987;60:1161–6
Maher EA, Shepherd FA, Todd TJR. Pericardial sclerosis as the primary management of malignant effusion and cardiac tamponade. J Thoracic Cardiovasc Surg 1996;112:637–43
Wang PC, et al. Prognostic role of pericardial fluid cytology in cardiac tamponade associated with non-small cell lung cancer. Chest 2000;118:744–9
Cullinane CA, Paz IB, Smith D, Carter N, Grannis FW Jr. Prognostic factors in the surgical management of pericardial effusion in the patient with concurrent malignancy. Chest 2004;125:1328–34
Okamoto H, Shinkai T, Yamakido M, Saijo N. Cardiac tamponade caused by primary lung cancer and the management of pericardial effusion. Cancer 1993;71:93–8
Allen KB, Faber LP, Warren WH, Shaar CJ. Pericardial effusion: subxiphoid pericardiostomy versus percutaneous catheter drainage. Ann Thoracic Surg 1999;67:437–40
Gornik HL, Gerhard-Herman M, Beckman JA. Abnormal cytology predict poor prognosis in cancer patients with pericardial effusion. J Clin Oncol 2005;23:5211–6
Tamura A, et al. Cardiac metastasis of lung cancer: a study of metastatic pathways and clinical manifestations. Cancer 1992;70:437–42
Hanfling SM. Meatstatic cancer to the heart. Circulation 1960;22:474–83
Fraser RS, Viloria JB, Wang NS. Cardiac tamponade as a presentation of extracardiac malignancy. Cancer 1980;45:1697–704
Buck M, Ingle JN, Giuliani ER, Gordon JR, Therneau TM. Pericardial effusion in woman with breast cancer. Cancer 1987;60:263–9
Nguyen DM, Schrump DS. Malignant pericardial effusion. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer, principles and practice of oncology. 7th ed. Philadelphia, PA: Lippincott Williams and Willkins; 2005. pp. 2387–2392
McDonald JM, et al. Comparison of open subxiphoid pericardial drainage with percutaneous catheter drainage for symptomatic pericardial effusion. Ann Thorac Surg 2003;76:811–5
Park JS, Rentschler R, Wilbur D. Surgical management of pericardial effusion in patients with malignancies. Comparison of subxiphoid window versus pericardiectomy. Cancer 1991;67:76–80
Vaitkus PT, Herrmann HC, LeWinter MM. Treatments of malignant pericardial effusion. JAMA 1994;272:59–64
Liu G, Crump M, Goss PE, Dancey J, Shepherd FA. Prospective comparison of the sclerosing agents doxycycline and bleomycin for the primary management of malignant pericardial effusion and cardiac tamponade. J Clin Oncol 1996;14:3141–7
Acknowledgement
Authors thank to Hajime Uno, (Division of Biostatistics, Kitasato University Graduate School), Shunichi Watanabe, Kenji Suzuki (Division of Thoracic Surgery, National Cancer Center Hospital), Tsutomu Kouno, Hiroshi Nokihara, Ikuo Sekine, Yuichiro Ohe (Division of Medical Oncology, National Cancer Center Hospital), and Yoshihiro Matsuno (Division of Clinical Laboratory, National Cancer Hospital) for their assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yonemori, K., Kunitoh, H., Tsuta, K. et al. Prognostic factors for malignant pericardial effusion treated by pericardial drainage in solid-malignancy patients. Med Oncol 24, 425–430 (2007). https://doi.org/10.1007/s12032-007-0033-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12032-007-0033-9